The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection

Table 1

Study	Study design	Population	Risk factors
PICNIC	Prospective	Infants hospitalized for RSV infections	(i) Underlying disease (CHD, CLD, immunodeficiency, multiple congenital malformations).; (ii) Postnatal age <6 weeks.; (iii) GA 33–35 weeks.
FLIP	Prospective case-control study	Preterm born at 33–35 weeks’ GA (risk factors for RSV-related hospitalization)	(i) Chronologic age ≤ 10 weeks at the beginning of RSV epidemic season.; (ii) Breastfeeding ≤ 2 months.; (iii) ≥1 school-age siblings.; (iv) ≥4 residents or visitors at home.; (v) Family history of wheezing.
Multicenter Italian birth cohort	Multicenter prospective cohort study	Infants born at 33 weeks’ GA or more	(i) GA 33 + 0–37 + 6 weeks; (ii) No breastfeeding.; (iii) Presence of siblings.; (iv) Maternal smoking.; (v) Family history of atopy or wheezing.